Seattle Genetics, Pfizer To Collaborate On Tumor Drug Technology

Seattle Genetics, Pfizer To Collaborate On Tumor Drug Technology

  • Posted Thursday, January 06, 2011 -
  • Share |
Seattle Genetics, Inc., a clinical-stage biotechnology company, Thursday announced a collaboration agreement with healthcare giant Pfizer Inc. by which Pfizer will utilize Seattle Genetics' rights for antibody-drug conjugate technology with antibodies to a single oncology target. Seattle Genetics will receive an upfront fee of $8 million from Pfizer.view original article

Related News Items